Market open
Greenwich LifeSciences/$GLSI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Greenwich LifeSciences
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
Ticker
$GLSI
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
6
ISIN
US3968791083
Website
GLSI Metrics
BasicAdvanced
$129M
-
-$1.21
3.38
-
Price and volume
Market cap
$129M
Beta
3.38
52-week high
$18.75
52-week low
$8.06
Average daily volume
120K
Financial strength
Current ratio
2.624
Quick ratio
2.624
Management effectiveness
Return on assets (TTM)
-180.50%
Return on equity (TTM)
-341.95%
Valuation
Price to book
50.3
Price to tangible book (TTM)
50.33
Price to free cash flow (TTM)
-17.355
Growth
Earnings per share change (TTM)
75.30%
3-year earnings per share growth (CAGR)
50.89%
What the Analysts think about GLSI
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Greenwich LifeSciences stock.
GLSI Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
GLSI News
AllArticlesVideos
Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial
GlobeNewsWire·1 month ago
Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026
GlobeNewsWire·2 months ago
Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Greenwich LifeSciences stock?
Greenwich LifeSciences (GLSI) has a market cap of $129M as of May 14, 2025.
What is the P/E ratio for Greenwich LifeSciences stock?
The price to earnings (P/E) ratio for Greenwich LifeSciences (GLSI) stock is 0 as of May 14, 2025.
Does Greenwich LifeSciences stock pay dividends?
No, Greenwich LifeSciences (GLSI) stock does not pay dividends to its shareholders as of May 14, 2025.
When is the next Greenwich LifeSciences dividend payment date?
Greenwich LifeSciences (GLSI) stock does not pay dividends to its shareholders.
What is the beta indicator for Greenwich LifeSciences?
Greenwich LifeSciences (GLSI) has a beta rating of 3.38. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.